{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:07:13Z","timestamp":1785528433730,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary Sj\u00f6gren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30\u201381) and 55 (19\u201386) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and significant LF (F2\u20134) [2 (3.8%) vs. 34 (17.2%), <jats:italic>p<\/jats:italic> = 0.014] than comparators. Univariable analysis showed that advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status (comparators than pSS); of these, only age was identified as an independent LF risk factor in the multivariable logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Liver fibrosis among pSS patients is most likely not attributed to the disease <jats:italic>per se<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.889021","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:34:43Z","timestamp":1655267683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Liver Fibrosis in Primary Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Theodoros","family":"Androutsakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros A.","family":"Voulgaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios-Dimitrios","family":"Bakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Loukia","family":"Koutsompina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Chatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania D.","family":"Argyropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Pezoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios I.","family":"Fotiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas V.","family":"Goules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(19)30039-1","article-title":"Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global Nafld Prevalence: A Systematic Review and Meta-Analysis","author":"Le","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14828","article-title":"Prevalence of Nafld, Mafld and Associated Advanced Fibrosis in the Contemporary United States Population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15139","article-title":"Systematically Comparing Epidemiological and Clinical Features of Mafld and Nafld by Meta-Analysis: Focusing on the Non-Overlap Groups","volume":"42","author":"Ayada","year":"2022","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50320","article-title":"Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C","volume":"38","author":"Hui","year":"2003","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the Natural History of Nonalcoholic Steatohepatitis: From Cryptogenic Cirrhosis to Hepatocellular Carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Easl-Easd-Easo Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22742","article-title":"Liver Biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C. The French Metavir Cooperative Study Group","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.015","article-title":"Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy","volume":"91","author":"Boyum","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive Imaging Biomarker Assessment of Liver Fibrosis by Elastography in Nafld","volume":"15","author":"Tapper","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31655","article-title":"Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in Nafld","volume":"73","author":"Cassinotto","year":"2021","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32163","article-title":"Population Screening for Liver Fibrosis: Toward Early Diagnosis and Intervention for Chronic Liver Diseases","volume":"75","author":"Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00005792-196505000-00001","article-title":"Sjoegren's Syndrome. A Clinical, Pathological, and Serological Study of Sixty-Two Cases","volume":"44","author":"Bloch","year":"1965","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(94)80007-3","article-title":"Autoimmune Liver Disease in Patients With Primary Sj\u00f6gren's Syndrome","volume":"20","author":"Lindgren","year":"1994","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.8.745","article-title":"Liver Involvement in Primary Sj\u00f6gren's Syndrome","volume":"33","author":"Skopouli","year":"1994","journal-title":"Br J Rheumatol"},{"key":"B21","article-title":"Characterization and Differentiation of Autoimmune Versus Viral Liver Involvement in Patients With Sj\u00f6gren's Syndrome","volume":"33","author":"Ramos-Casals","year":"2006","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31920-9","article-title":"Abnormal Hepatic Biochemistries and Clinical Liver Disease in Patients With Primary Sj\u00f6gren's Syndrome","volume":"6","author":"Monta\u00f1o-Loza","year":"2007","journal-title":"Ann Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-2-21","article-title":"The Liver Is a Common Non-Exocrine Target in Primary Sj\u00f6gren's Syndrome: A Retrospective Review","volume":"2","author":"Kaplan","year":"2002","journal-title":"BMC Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-200101000-00001","article-title":"Hepatitis C Virus Infection Mimicking Primary Sj\u00f6gren Syndrome. A Clinical and Immunologic Description of 35 Cases","volume":"80","author":"Ramos-Casals","year":"2001","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390714","article-title":"Sicca Syndrome Associated With Hepatitis C Virus Infection","volume":"39","author":"Jorgensen","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MCG.0b013e3182329d9c","article-title":"Gastrointestinal and Hepatic Manifestations of Sjogren Syndrome","volume":"46","author":"Ebert","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8471-1","article-title":"The Coexistence of Sj\u00f6gren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review","volume":"48","author":"Sun","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Easl Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis - 2021 Update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of Fibroscan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/ep171764.Appgl","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"B32","unstructured":"Drinking Levels Defined2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sj\u00f6gren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","article-title":"Eular Sj\u00f6gren's Syndrome Disease Activity Index (Essdai): A User Guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1113629","article-title":"Clinical Predictors of Silent But Substantial Liver Fibrosis in Primary Sjogren's Syndrome","volume":"26","author":"Lee","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.3390\/cells10123604","article-title":"Metabolic Reprogramming of Liver Fibrosis","volume":"10","author":"Delgado","year":"2021","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/cells10102759","article-title":"Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression","volume":"10","author":"Caligiuri","year":"2021","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and Cellular Mechanisms of Liver Fibrosis and Its Regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.889021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:34:46Z","timestamp":1655267686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.889021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.889021"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.889021","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"889021"}}